CMTM6 (CKLF like MARVEL transmembrane domain containing 6)

2018-02-01  

Identity

HGNC
LOCATION
3p22.3
LOCUSID
ALIAS
CKLFSF6,PRO2219
FUSION GENES

Other Information

Locus ID:

NCBI: 54918
MIM: 607889
HGNC: 19177
Ensembl: ENSG00000091317

Variants:

dbSNP: 54918
ClinVar: 54918
TCGA: ENSG00000091317
COSMIC: CMTM6

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000091317ENST00000205636Q9NX76

Expression (GTEx)

0
10
20
30
40
50
60
70
80

Pathways

PathwaySourceExternal ID
Immune SystemREACTOMER-HSA-168256
Innate Immune SystemREACTOMER-HSA-168249
Neutrophil degranulationREACTOMER-HSA-6798695

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
380821562024From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6.0
381139792024Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.2
381657042024Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.1
382215632024CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.0
386866532024Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.0
380821562024From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6.0
381139792024Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.2
381657042024Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.1
382215632024CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.0
386866532024Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.0
366276082023CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.8
366436292023CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.1
368155102023CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.2
366276082023CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.8
366436292023CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.1

Citation

Dessen P

CMTM6 (CKLF like MARVEL transmembrane domain containing 6)

Atlas Genet Cytogenet Oncol Haematol. 2018-02-01

Online version: http://atlasgeneticsoncology.org/gene/57316/